Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|July 8, 2022
Daily OTC Pearl: BurnAid
Author(s)Saro Arakelians, PharmD
BurnAid burn dressing provides relief for all types of minor burns.
Advertisement
OTC/Lifestyle Pearl of the Day: BurnAid
Indication: BurnAid burn dressing provides relief for all types of minor burns.
Insight:
- Sterile gel dressing.
- Moist dressing to prevent contamination.
- Contains a surgical foam.
- Good for emergency burns and relieving pain.
- Comes in various sizes of 10x10 or 20x20cm, depending on the need.
Advertisement
Related to this article
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Ramantamig's 93.6% ORR and Outpatient CRS Control
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
5